
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Practice Tips From the Updated Helicobacter pylori Treatment Guidelines</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Practice Tips From the Updated Helicobacter pylori Treatment Guidelines</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology &amp; Hepatology, Volume 22, Issue 2, February 2026</li>
<li style="margin-left: 0px;">Topic: Updated ACG H. pylori Treatment Guidelines (2024 vs 2017)</li>
<li style="margin-left: 0px;">Author(s): Martin Ventoso, MD, and Steven F. Moss, MD</li>
</ul>
<details><summary><strong>1. Background &amp; Epidemiology</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Disease burden</strong>: H. pylori causes chronic gastritis → peptic ulcer disease, gastric adenocarcinoma, MALT lymphoma</li>
<li style="margin-left: 0px;"><strong>Extra-gastric associations</strong>: iron-deficiency anemia, idiopathic thrombocytopenic purpura (ITP), dyspepsia</li>
<li style="margin-left: 0px;"><strong>Global prevalence trend</strong>: ↓ from 58.2% (1980–1990) to 43.1% (2011–2022)</li>
<li style="margin-left: 0px;"><strong>US prevalence</strong>: ~one-third of adults infected; precise recent estimates lacking</li>
<li style="margin-left: 0px;"><strong>High-risk US groups</strong>: elderly (age cohort effect), minority populations, first-generation immigrants from endemic areas (Central/South America, East Asia, Sub-Saharan Africa, Eastern Europe)</li>
</ul>
</div></details>
<details><summary><strong>2. Guideline Overview &amp; Methodology</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>2024 ACG guidelines</strong>: 5 recommendations for treatment-naive patients + 7 for refractory cases + 6 key concepts</li>
<li style="margin-left: 0px;"><strong>Development</strong>: GRADE methodology; clinical experts + gastroenterology methodologists</li>
<li style="margin-left: 0px;"><strong>Key change</strong>: shift from empiric to biology-based (antimicrobial susceptibility-guided) therapy</li>
<li style="margin-left: 0px;"><strong>Comparison base</strong>: 2017 ACG guidelines relied heavily on non-North American data</li>
</ul>
</div></details>
<details><summary><strong>3. First-Line Treatment: Optimized Bismuth Quadruple Therapy</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Rationale for Preference</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clarithromycin resistance &gt;30% in US → clarithromycin triple therapy unacceptable efficacy</li>
<li style="margin-left: 0px;">Supported by 3 US retrospective series (Rhode Island, US military, national claims database)</li>
<li style="margin-left: 0px;"><strong>Eradication rates</strong>: 85–87% (bismuth quadruple) vs 76–80% (clarithromycin triple)</li>
<li style="margin-left: 0px;"><strong>Duration</strong>: 14 days (standard for all 2024 regimens); exception: Pylera 10-day pack</li>
</ul>
</div></details>
<details><summary><strong>3.2 Optimized Regimen Specifications</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Drug</th>
<th>Dosing</th>
<th>Notes</th>
</tr></thead>
<tbody>
<tr>
<td><strong>PPI</strong></td>
<td>Twice-daily standard dose, 30–60 min before breakfast/dinner</td>
<td>Esomeprazole or rabeprazole preferred; pantoprazole nonpreferred</td>
</tr>
<tr>
<td><strong>Bismuth</strong></td>
<td>≥300 mg bismuth subsalicylate 4× daily OR 120–300 mg bismuth subcitrate 4× daily</td>
<td>Salicylate allergy: substitute bismuth subcitrate or use branded Pylera</td>
</tr>
<tr>
<td><strong>Tetracycline</strong></td>
<td>500 mg 4× daily</td>
<td>Do NOT substitute doxycycline</td>
</tr>
<tr>
<td><strong>Metronidazole</strong></td>
<td>500 mg 3–4× daily (&gt;1.5 g/day)</td>
<td>Overcomes in vitro resistance</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Penicillin safety</strong>: Bismuth quadruple contains no penicillin → safe for true penicillin allergy</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. New FDA-Approved Treatment Regimens</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Rifabutin Triple Therapy (Talicia)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Composition</strong>: rifabutin 150 mg + amoxicillin 3 g + omeprazole 120 mg daily</li>
<li style="margin-left: 0px;"><strong>Efficacy</strong>: 84% eradication (modified ITT) vs 58% in comparator arm (amoxicillin + omeprazole only)</li>
<li style="margin-left: 0px;"><strong>Generic substitution</strong>: omeprazole 40 mg + amoxicillin 1 g each 3× daily; rifabutin 150 mg 2× daily (not once daily)</li>
<li style="margin-left: 0px;"><strong>PK rationale</strong>: Generic rifabutin 150 mg QD inferior to 50 mg TID (as in combination tablet)</li>
<li style="margin-left: 0px;"><strong>Limitation</strong>: Cannot use with confirmed penicillin allergy</li>
</ul>
</div></details>
<details><summary><strong>4.2 Vonoprazan-Based Therapy (P-CAB)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Mechanism</strong>: Potassium-competitive acid blocker; targets parietal cell proton pump</li>
<li style="margin-left: 0px;"><strong>Advantages over PPI</strong>: More potent, faster-acting, efficacy independent of meal timing</li>
<li style="margin-left: 0px;"><strong>Trial results</strong> (US/Europe, treatment-naive):</li>
<li style="margin-left: 20px;">Vonoprazan + clarithromycin + amoxicillin: <strong>81%</strong> eradication</li>
<li style="margin-left: 20px;">Lansoprazole + clarithromycin + amoxicillin: <strong>69%</strong> eradication</li>
<li style="margin-left: 20px;">Vonoprazan + amoxicillin dual therapy: <strong>77%</strong> eradication → FDA-approved both regimens</li>
<li style="margin-left: 0px;"><strong>Limitation</strong>: Not directly compared with bismuth quadruple therapy; real-world performance TBD</li>
</ul>
</div></details>
<details><summary><strong>4.3 Guideline Recommendations for New Regimens</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Strength</strong>: Conditional (suggested) recommendations; weaker than &quot;recommended&quot; (bismuth quadruple)</li>
<li style="margin-left: 0px;"><strong>Evidence quality</strong>: Low to moderate</li>
<li style="margin-left: 0px;"><strong>Rifabutin triple therapy</strong>: Suggested as empiric first-line alternative (non-penicillin-allergic patients)</li>
<li style="margin-left: 0px;"><strong>Vonoprazan-amoxicillin dual therapy</strong>: Suggested first-line option</li>
<li style="margin-left: 0px;"><strong>Dual PPI-amoxicillin therapy</strong>: NOT recommended</li>
<li style="margin-left: 0px;"><strong>Penicillin allergy</strong>: Neither rifabutin nor vonoprazan regimens suitable (both require amoxicillin)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Antimicrobial Resistance &amp; Susceptibility Testing</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 US Resistance Rates (2011–2021 meta-analysis)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Metronidazole: <strong>42.1%</strong></li>
<li style="margin-left: 0px;">Levofloxacin: <em></em>37.</li>
</ul>
</div></details>
<details><summary><strong>5.1 US Resistance Rates (continued)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clarithromycin: <strong>31.5%</strong></li>
<li style="margin-left: 0px;">Amoxicillin: <strong>2.6%</strong></li>
<li style="margin-left: 0px;">Tetracycline: <strong>0.87%</strong></li>
<li style="margin-left: 0px;">Rifabutin: <strong>0.17%</strong> (lowest resistance)</li>
<li style="margin-left: 0px;">Dual clarithromycin + metronidazole resistance: <strong>11.7%</strong></li>
<li style="margin-left: 0px;">Alternative study (907 US/EU participants from vonoprazan trial): clarithromycin 22.2%, amoxicillin 1.2%, metronidazole 69.2%</li>
</ul>
</div></details>
<details><summary><strong>5.2 Clinical Implications of Resistance Data</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>High clarithromycin/levofloxacin resistance</strong>: Underlies strong recommendation against empiric use</li>
<li style="margin-left: 0px;"><strong>2017 approach</strong>: Used prior antibiotic exposure as surrogate predictor of resistance</li>
<li style="margin-left: 0px;"><strong>2024 approach</strong>: Encourages antimicrobial susceptibility testing, especially in refractory cases and definite penicillin allergy</li>
</ul>
</div></details>
<details><summary><strong>5.3 Susceptibility Testing Methods</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Traditional culture</strong>: Limited by exacting gastric biopsy requirements and specimen transport challenges</li>
<li style="margin-left: 0px;"><strong>Molecular methods</strong> (preferred): PCR and next-generation sequencing using gastric biopsies or stool specimens</li>
<li style="margin-left: 0px;"><strong>Practical barriers</strong>: Costs and reimbursement issues remain unresolved</li>
<li style="margin-left: 0px;"><strong>Guideline recommendation</strong>: Providers should explore local testing availability; consult infectious disease, microbiology, and pathology colleagues</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Refractory/Salvage Treatment Algorithms</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Algorithm Without Susceptibility Testing</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Penicillin-allergic patients</strong>: Limited options → essentially only optimized bismuth quadruple therapy available</li>
<li style="margin-left: 0px;"><strong>No prior bismuth quadruple</strong>: Suggest optimized bismuth quadruple over quinolone-based therapy</li>
<li style="margin-left: 0px;"><strong>Prior PPI-clarithromycin triple failure</strong>: Suggest optimized bismuth quadruple therapy</li>
<li style="margin-left: 0px;"><strong>Prior bismuth quadruple failure</strong>: Suggest rifabutin triple therapy</li>
</ul>
</div></details>
<details><summary><strong>6.2 Algorithm With Susceptibility Testing</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Clarithromycin-containing regimens</strong>: Avoid unless susceptibility confirmed</li>
<li style="margin-left: 0px;"><strong>Levofloxacin-based therapy</strong>: Suggest only with known levofloxacin-sensitive strains; reserved for when other treatments failed or unavailable (adverse event profile + black-box warning concerns)</li>
<li style="margin-left: 0px;"><strong>Guided regimen selection</strong>: Based on individual susceptibility patterns</li>
</ul>
</div></details>
<details><summary><strong>6.3 Evidence Quality for Salvage Therapy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">All refractory treatment recommendations: <strong>conditional</strong> (weaker)</li>
<li style="margin-left: 0px;">Evidence base: Low to very low quality</li>
<li style="margin-left: 0px;"><strong>Key gap</strong>: Lack of US clinical trials for salvage treatments</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Gastric Cancer Prevention &amp; Screening</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Evidence for Eradication Benefit</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Study Type</th>
<th>Risk Reduction</th>
</tr></thead>
<tbody>
<tr>
<td>RCTs in H. pylori-positive healthy individuals (meta-analysis)</td>
<td>36% reduction</td>
</tr>
<tr>
<td>RCTs in patients post-endoscopic gastric cancer resection (meta-analysis)</td>
<td>48% reduction</td>
</tr>
<tr>
<td>RCT in first-degree relatives of gastric cancer patients</td>
<td>55% reduction</td>
</tr>
<tr>
<td>Population screening/treating (Matsu Islands, Taiwan)</td>
<td>50% reduction</td>
</tr>
<tr>
<td>Retrospective: VA cohort</td>
<td>76% reduction</td>
</tr>
<tr>
<td>Retrospective: Kaiser Permanente Northern California (≥8 years follow-up)</td>
<td>63% reduction (noncardia cancer)</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>7.2 US-Specific Data</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VA cohort</strong> (371,813 patients): Higher gastric cancer risk in racial/ethnic minorities and smokers; H. pylori eradication → 75% risk reduction</li>
<li style="margin-left: 0px;"><strong>Kaiser Permanente</strong> (716,567 enrollees): Eradication therapy → 63% reduced incidence of noncardia gastric adenocarcinoma after 8 years</li>
</ul>
</div></details>
<details><summary><strong>7.3 Screening Recommendations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Universal screening</strong>: NOT currently recommended in ACG 2024 guidelines</li>
<li style="margin-left: 0px;"><strong>Focused testing and treatment</strong>: Appropriate starting at age <strong>45–50 years</strong></li>
<li style="margin-left: 0px;"><strong>Target populations</strong>: Non-White racial/ethnic groups, immigrants from high cancer incidence regions</li>
<li style="margin-left: 0px;"><strong>Rationale</strong>: These groups have highest US gastric cancer rates</li>
</ul>
</div></details>
<details><summary><strong>7.4 International Context</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Countries with screening programs</strong>: Japan, Korea</li>
<li style="margin-left: 0px;"><strong>European trials</strong>: Several ongoing H. pylori screening trials</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Comparative Guidelines Analysis</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 ACG 2024 vs Maastricht VI/Florence 2022</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Aspect</th>
<th>ACG 2024</th>
<th>Maastricht 2022</th>
</tr></thead>
<tbody>
<tr>
<td><strong>Rifabutin use</strong></td>
<td>First/second-line therapy</td>
<td>Reserve for ≥2 prior treatment failures</td>
</tr>
<tr>
<td><strong>Levofloxacin</strong></td>
<td>Recommend against empiric use; require susceptibility testing</td>
<td>Suitable empiric second-line choice</td>
</tr>
<tr>
<td><strong>Clarithromycin</strong></td>
<td>Only with confirmed susceptibility</td>
<td>Not mandated for susceptibility testing</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>8.2 Other Guidelines</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>WGO Global Guideline</strong>: Intended for resource-poor countries</li>
<li style="margin-left: 0px;"><strong>ACG iterations</strong>: 2007 → 2017 → 2024</li>
</ul>
</div></details>
<details><summary><strong>8.3 Guideline Limitations &amp; Criticism</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Common criticisms</strong>: Outdated, inaccessible, irrelevant, subject to bias</li>
<li style="margin-left: 0px;"><strong>Conflict of interest mitigation</strong>: Open declaration for peer judgment</li>
<li style="margin-left: 0px;"><strong>Purpose</strong>: Complement clinical judgment, not replace it</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Implementation Gap &amp; Practice Patterns</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Current US Prescribing Reality</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary care</strong>: Majority of H. pylori prescriptions; may not follow latest guidelines</li>
<li style="margin-left: 0px;"><strong>2017 guideline recommendation</strong>: Confine clarithromycin triple therapy to patients with no macrolide exposure + low clarithromycin resistance areas</li>
<li style="margin-left: 0px;"><strong>Market reality</strong>: Clarithromycin-PPI triple therapy comprised &gt;80% of US treatments (2016–2019)</li>
<li style="margin-left: 0px;"><strong>Failure handling</strong>: ~50% of clarithromycin-PPI triple therapy failures received exact same prescription again</li>
</ul>
</div></details>
<details><summary><strong>9.2 Dissemination Challenges</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Specialty journal limitation</strong>: Published in American Journal of Gastroenterology (gastroenterology-focused)</li>
<li style="margin-left: 0px;"><strong>Wider dissemination needs</strong>: </li>
<li style="margin-left: 20px;">Update platforms (UpToDate, OpenEvidence)</li>
<li style="margin-left: 20px;">Modify EMR care algorithms</li>
<li style="margin-left: 20px;">Change pharmacy/insurance plan recommendations</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Knowledge Gaps &amp; Future Research Priorities</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Identified Gaps</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Screening optimization</strong>: Which individuals benefit most from H. pylori screening for gastric cancer prevention?</li>
<li style="margin-left: 0px;"><strong>Comparative efficacy trials</strong>: Novel treatments vs optimized bismuth quadruple therapy (</li>
</ul>
</div></details>
<details><summary><strong>10.1 Identified Gaps (continued)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Refractory treatment efficacy</strong>: Lack of US data on salvage treatments is disappointing and should be addressed</li>
<li style="margin-left: 0px;"><strong>Susceptibility testing trials</strong>: Need for RCTs comparing susceptibility testing-based treatment vs empiric therapy to formally test hypothesis that tailored therapy improves outcomes</li>
<li style="margin-left: 0px;"><strong>Treatment registry</strong>: Ongoing efforts to establish US H. pylori treatment registry (modeled on Europe and Latin America) may help address data gaps</li>
</ul>
</div></details>
<details><summary><strong>10.2 Future Directions</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>P-CABs likely to replace PPIs</strong>: Given importance of acid suppression in vivo bacterial killing</li>
<li style="margin-left: 0px;"><strong>Recent network meta-analysis</strong> (post-guideline): Recommended P-CAB–amoxicillin as most efficacious regimen overall</li>
<li style="margin-left: 20px;"><strong>Caveat</strong>: 24 of 25 included studies from East Asia where dual therapies perform better than in West (reasons unclear)</li>
<li style="margin-left: 0px;"><strong>Novel combinations needed</strong>: To achieve ≥90% eradication rates in US → combining P-CAB–amoxicillin dual therapy with rifabutin and/or bismuth and/or tetracycline</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Conclusions</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>2024 ACG guidelines</strong>: Major shift from empiric to biology-based (susceptibility-guided) therapy</li>
<li style="margin-left: 0px;"><strong>First-line preference</strong>: Optimized bismuth quadruple therapy (14 days)</li>
<li style="margin-left: 0px;"><strong>New alternatives</strong>: Rifabutin triple therapy, vonoprazan-based regimens (suggested, not recommended)</li>
<li style="margin-left: 0px;"><strong>Key principle</strong>: Avoid clarithromycin/levofloxacin unless susceptibility confirmed</li>
<li style="margin-left: 0px;"><strong>Screening focus</strong>: Targeted testing in high-risk groups (age 45–50, non-White/ethnic minorities, immigrants from endemic areas) for gastric cancer prevention</li>
<li style="margin-left: 0px;"><strong>Implementation gap</strong>: &gt;80% of US prescriptions still clarithromycin-based; major dissemination needed to primary care</li>
<li style="margin-left: 0px;"><strong>Evolution expected</strong>: Field will continue rapid evolution; P-CABs likely central to future regimens</li>
</ul>
</div></details>
<details><summary><strong>12. Disclosures</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dr Ventoso</strong>: No relevant conflicts of interest</li>
<li style="margin-left: 0px;"><strong>Dr Moss</strong>: Consultant to Meridian Bioscience; royalties as UpToDate author; author of 2017 and 2024 ACG H. pylori guidelines</li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
